[en] We provide here a new set of data supporting the involvement of multiple platelet receptors in CpG ODN platelet activating effects. We observed some sequence-specific features of platelet responses to phosphorothioate-modified CpG ODNs types A, B, and C that could be useful for future development of safe therapeutic CpG ODNs. Additional investigations are needed in order to further delineate these sequence specificities, and to address the importance of higher-order structures, as well as of possible interactions with cofactors for the effects of CpG ODN on platelets.
Disciplines :
Hematology
Author, co-author :
Delierneux, Céline; Université de Liège - ULiège > GIGA-Cardiovascular Sciences
Donis, Nathalie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Servais, Laurence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Wéra, Odile ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > Service de cardiologie
Oury, Cécile ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Language :
English
Title :
Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply.
Delierneux C, Donis N, Servais L, Wera O, Lecut C, Vandereyken M, Musumeci L, Rahmouni S, Schneider J, Eble JA, Lancellotti P, Oury C. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides. J Thromb Haemost 2017; 15: 983–97.
Flierl U, Nero TL, Lim B, Arthur JF, Yao Y, Jung SM, Gitz E, Pollitt AY, Zaldivia MT, Jandrot-Perrus M, Schafer A, Nieswandt B, Andrews RK, Parker MW, Gardiner EE, Peter K. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med 2015; 212: 129–37.
Dalpke AH, Zimmermann S, Albrecht I, Heeg sK. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002; 106: 102–12.
Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep 2012; 2: 534.
Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, Johnson J, Englert S, Ketterer T, Heckl W, Thalhammer S, Endres S, Hartmann G. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem 2005; 280: 8086–93.
Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomed 2012; 7: 2181–95.
Gursel M, Gursel I, Mostowski HS, Klinman DM. CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol 2006; 177: 1575–80.
Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1996; 24: 737–45.
Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003; 102: 3609–14.
Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, Weitz JI, Rand ML, Mosher DF, Freedman J, Ni H. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014; 124: 4281–93.